510(k) Report

510(k) · Cleared

Cleared

Immulite/Immulite 1000 OM-MA, Immulite 2000 OM-MA

K213510510(k) TraditionalCleared Sep 8, 2023675-day reviewClass II21 CFR 866.6010

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Siemens Healthcare Diagnostics Products, Ltd. · LTK Test, Epithelial Ovarian Tumor-Associated Antigen (Ca125)

Cleared on Sep 8, 2023 as substantially equivalent to K981297 (Diagnostic Products Corp., 1998) and 1 other predicate after a 675-day review. Its family tree reaches back 2 generations to 1998.

Decided
Sep 8, 2023
Review
675 days
Class
Class II
Product code
LTK
Recalls
None
Predicates
2

Its longest line of descent runs back 2 generations to K981297 (1998). No later device cites it as a predicate yet.

×2: 2 generations cleared close together, K981297 (1998), K983391 (1998) 1995200020052010201520202025
  1. Root · 2 generations backK981297 Immulite OM-MA, Models Lkopz, LKOP1, LKOP5Diagnostic Products Corp. · 1998 · Recalled
  2. 1 generation backK983391 Immulite 2000 OM-MA Model L2KOP2Diagnostic Products Corp. · 1998 · Recalled
  3. This deviceK213510 Immulite/Immulite 1000 OM-MA, Immulite 2000 OM-MASiemens Healthcare Diagnostics Products, Ltd. · 2023
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K981297Immulite OM-MA, Models Lkopz, LKOP1, LKOP5Diagnostic Products Corp.19981
−1K983391Immulite 2000 OM-MA Model L2KOP2Diagnostic Products Corp.19981
0 (this device)K213510Immulite/Immulite 1000 OM-MA, Immulite 2000 OM-MASiemens Healthcare Diagnostics Products, Ltd.2023—
FIG. 1 — Lineage of K213510, 1998–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LTK? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LTK device

  1. #1 K240479 Access OV Monitorscore 7.3 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K981297Immulite OM-MA, Models Lkopz, LKOP1, LKOP5
Summary page 4
…OM-MA and IMMULITE 2000 OM-MA, manufactured by Siemens Healthcare Diagnostics Products Ltd, Glyn Rhonwy, Llanberis, Wales, United Kingdom, were cleared by the FDA under K981297 and K983391. 5.4 Device Description The IMMULITE®/IMMULITE 1000 OM-MA Assay is comprised of the following compon…
Diagnostic Products Corp.19981
*K983391Immulite 2000 OM-MA Model L2KOP2
Summary page 4
…MMULITE 2000 OM-MA, manufactured by Siemens Healthcare Diagnostics Products Ltd, Glyn Rhonwy, Llanberis, Wales, United Kingdom, were cleared by the FDA under K981297 and K983391. 5.4 Device Description The IMMULITE®/IMMULITE 1000 OM-MA Assay is comprised of the following components: Comp…
Diagnostic Products Corp.19981

Also cleared against K981297: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 25 years and passes through 2 companies; a new generation was cleared every 24.9 years on median.
  • 2 of the 2 ancestors have a recall of any class.
  • 1 other device also cites its predicate K981297.

How does its category compare?

All LTK devices

LTK Test, Epithelial Ovarian Tumor-Associated Antigen (Ca125): FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · LTK

1in 2024

2007: 12009: 22011: 12015: 22020: 12022: 12023: 12024: 1
2007high 2 (2009) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LTK

Too few LTK 510(k)s in any year since 2007 to give a median.

Recalls per year · LTK

1in 2013

2007: 12010: 32013: 1
2007high 3 (2010) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LTK

4in 2025

2007: 42008: 92009: 312010: 122011: 52012: 332013: 142014: 302015: 112016: 42017: 152018: 82019: 152020: 52021: 22022: 22023: 62024: 62025: 4
2007high 33 (2012) · low 2 (2021)2025

MAUDE reports naming product code LTK, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—14
20080—09
20092—031
20100—312
20111—05
20120—033
20130—114
20140—030
20152—011
20160—04
20170—015
20180—08
20190—015
20201—05
20210—02
20221—02
20231—06
20241—06
20250—04
20260—0—

What is it indicated for?

For in vitro diagnostic use with the IMMULITE® and IMMULITE® 1000 Analyzers — for the quantitative measurement of CA125 antigen in serum, as an aid in monitoring the response to therapy for patients with epithelian ovarian cancer, and in detecting residual ovarian cancer in patients who have undergone first-line therapy and would be considered for diagnostic second look procedures. For in vitro diagnostic use with the IMMULITE® 2000 Systems Analyzers —…

Read the full statement (116 words)

For in vitro diagnostic use with the IMMULITE® and IMMULITE® 1000 Analyzers — for the quantitative measurement of CA125 antigen in serum, as an aid in monitoring the response to therapy for patients with epithelian ovarian cancer, and in detecting residual ovarian cancer in patients who have undergone first-line therapy and would be considered for diagnostic second look procedures.

For in vitro diagnostic use with the IMMULITE® 2000 Systems Analyzers — for the quantitative measurement of CA125 antigen in serum, as an aid in monitoring the response to therapy for patients with epithelian ovarian cancer, and in detecting residual ovarian cancer in patients who have undergone first-line therapy and would be considered for diagnostic second-look procedures.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K213510: Immulite/Immulite 1000 OM-MA, Immulite 2000 OM-MA.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K213510

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026